NorthStar RxLLC announced on October 20, 2023, that the FDA has granted approval for its Oxcarbazepine tablet, ANDA 216749, offering a potential high-demand generic alternative to Trileptal and strengthening the company's portfolio in the anticonvulsant market. This launch is expected to boost NorthStar RxLLC’s revenue streams by capitalizing on the established sales volume of the branded anticonvulsant and intensifying competitive pricing in the neurology sector.